Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

BICO’s group companies CELLINK and CYTENA win five German Design Awards for Excellent Product Design

The prestigious awards validate the BICO’s Bio Convergence agenda and comes on the 10[th] anniversary of the widely respected design competitionFive products from BICO, the world’s leading Bio Convergence company, has been awarded with the prestigious 2022 German Design Awards. The recognition comes from the widely respected German Design Council and include awards and special mentions for devices from BICO’s group companies, CELLINK and CYTENA. The awards will be officially presented at the German Design Award show in February 2022. “Today’s lab instrument is often technical and hard to

Novedo has successfully issued senior secured bonds of SEK 750 million

Novedo Holding AB (publ) (“Novedo” or the “Company”) has successfully issued inaugural senior secured bond loan in the amount of SEK 750 million, under a total framework of SEK 1,500 million (the “Bonds”). The Bonds carry a floating interest rate of 3m STIBOR + 650 basis points with final maturity in November 2024. The transaction received strong interest from Nordic and international institutional investors and the books were significantly oversubscribed. The net proceeds from the Bonds will be applied towards refinancing of existing bank debt in the Company and towards acquisitions. It

iLOQ’s digital locking and access management system for Vaasa Central Hospital’s H building

The Vaasa Hospital District, which is made up of municipalities in the coastal region of Ostrobothnia, is responsible for providing specialized healthcare services to a population of almost 170,000 people. The area stretches from the municipality of Luodo in the north to Kristiinankaupunki in the south. Photo: Bothnia High 5 Alliance image bank Opening in 2022, the new H-building, built using the alliance model, is the largest construction project in the history of the Vaasa Hospital District. With a total surface area of 37,000 m[2], the new premises located in Hietalahti will

Aker ASA: SalMar Aker Ocean established

Reference is made to the announcement on 26 August 2021 regarding the entering into of a strategic partnership with SalMar ASA (“SalMar”) to establish a global offshore aquaculture company. The closing of the transaction has now taken place and the new joint company, SalMar Aker Ocean AS (“Salmar Aker Ocean”) has been established.SalMar Aker Ocean will operate within offshore fish farming, including offshore and semi-offshore. By combining Aker and SalMar’s industry experience, leading competence in salmon production, software, and cleantech the aim is to create the world’s most reliable

BioStock: Respiratorius has taken several steps this autumn

Lund-based drug developer Respiratorius has reported several important milestones during the autumn. Among other things, its cash position was strengthened at the beginning of the third quarter, and positive preclinical results was reported in the RESP9000 project. BioStock contacted the company’s CEO Johan Drott for a comment on the third quarter and what milestones he is looking forward to.Read the full article at biostock.se:https://www.biostock.se/en/2021/11/respiratorius-has-taken-several-steps-this-autumn/This is a press release from BioStock - Connecting Innovation & Capital.

Nordic Choice Hotels signing a strategic AI contract

Nordic Choice Hotels is one of the largest hotel groups in the Nordic and Baltic region. With over 300 hotels and companies in Norway, Sweden, Denmark and Finland. They have an annual revenue of more than 12 billion NOK and over 15,000 employees. Nordic Choice Hotels will produce millions of documents through the AI platform during the contract period. They are the first Enterprise customer pan-Nordic to implement the solution in 4 countries and with that they will be one of the most important strategic customers for new markets and countries. To maintain their leading position, they

Speqta recruits Sofia Björk as new Head of People

Speqta (”SPEQT”) has recruited and appointed Sofia Björk as Head of People. Sofia is currently at Advisa where she is CHRO (Chief Human Resource Officer). Sofia Björk joined Advisa more than three years ago and has been leading their HR team focusing on tech recruitment, employer branding and building the culture in a fast-growing SaaS-company. Sofia has a bachelor’s degree in HR and organization at Uppsala University where she also studied law. Speqta’s CEO Fredrik Lindros comments:We are very happy to have Sofia joining us on our journey. She has both a broad experience of

Swedbank included in the Dow Jones Sustainability Index 2021

Swedbank is included in the Dow Jones Sustainability Index for the second year in a row. The DJSI is a leading index for the world’s most sustainable businesses.Swedbank is included in the index based on an assessment made by S&P, the Corporate Sustainability Assessment, which covers areas such as corporate governance, risk management, brand building, human rights, climate change and labour practices. ‘’We strive to constantly develop our work with sustainability. This is the core of Swedbank’s business strategy. Our vision is a financially sound and sustainable society,’’ says Swedbank

Jakob Lindberg appointed CEO of Oncopeptides

STOCKHOLM — November 15, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the Board of Directors has appointed Jakob Lindberg as Chief Executive Officer, CEO  of Oncopeptides.  Jakob Lindberg replaces Marty J Duvall, who has been the CEO since July 1, 2020.  These changes are effective immediately.The leadership changes follows the withdrawal of Pepaxto[® ](INN melphalan flufenamide) from the US market and the company’s need to focus its resources on

AcuCort announces that the registration process in the Nordic market is underway for the company’s drug ISICORT®

AcuCort AB (Spotlight Stock Market: ACUC) announced today that the registration process in Denmark, Finland, Iceland and Norway regarding the company’s drug ISICORT® is currently ongoing via a so-called reciprocal procedure, Mutual Recognition Process (MRP). ISICORT® has previously been approved in Sweden.In the development of ISICORT®, the advantages of the commonly prescribed and well-documented anti-inflammatory substance dexamethasone and the administration of a fast-dissolving oral film have been combined into a new drug. The innovative drug has a rapid uptake of the active

FluoGuide A/S publishes interim report for the period January – September 2021

Copenhagen, Denmark, 15 November 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) today releases its results for the period 1 January – 30 September 2021. The Q3 report is available as an attached document to this press release and on FluoGuide’s website.Copenhagen, Denmark, 15 November 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) today releases its results for the period 1 January – 30 September 2021. The Q3 report is available as an attached document to this press release and on FluoGuide’s website. [][]Summary Q3 2021 Q3 2020 Q1-Q3 2021 Q1-Q3 2020

Saab Signs Contract for new Underwater Robot to Ocean Infinity

A contract has been signed with launch-customer Ocean Infinity for the latest Saab underwater robot.Saab, a world leader in underwater robotics, has agreed to sell 10 of its new electric work remotely operated vehicles (eWROV), including further options, to leading marine robotics company, Ocean Infinity. The eWROV is the latest addition to Saab Seaeye’s underwater portfolio used across a variety of offshore energy sectors, ocean science and defence. It is the culmination of four years of research and development, resulting in the largest and most powerful ROV compared to those designed

Autoliv and SSAB collaborate to produce the world’s first fossil-free steel components in automotive safety products

(Stockholm, Sweden, November 15, 2021) – Autoliv, Inc. (NYSE: ALV and SSE: ALIVsdb), the worldwide leader in automotive safety systems, and global steel company SSAB, have initiated a collaboration to research and develop fossil-free steel components for automotive safety products, such as airbags and seatbelts. The collaboration enables Autoliv to be in the forefront in producing automotive safety products with fossil-free steel from SSAB. A new process aims to replace coking coal, traditionally needed for ore-based steelmaking, with hydrogen. The result will be unique: the world's

Karin Schreil takes office as CEO of Ework Group

Today, Karin Schreil takes office as CEO of Ework Group. She succeeds Zoran Covic, who will remain as an advisor to the company's management for a transitional period. “I am very much looking forward to leading the company's continued development together with Ework's employees, clients and consultants. As Northern Europe's leading consulting broker, Ework is perfectly positioned to enable the ongoing digital transition in businesses and society in general,” comments Karin Schreil.Karin Schreil has extensive experience from leading positions in the consulting and talent markets, most

The last day of trading with the warrants of series TO1 in Realfiction Holding AB is today, 15 November 2021

Not for release, publication or distribution in whole or in part, directly or indirectly, in the United States, Australia, Canada, New Zealand, Hong Kong, Japan, Singapore, South Africa, South Korea or any other jurisdiction where such release, publication or distribution would be unlawful or would require registration or any other measures. Please refer to important information at the end of the press release. Today, 15 November 2021, is the last day of trading with the warrants of series TO1 in Realfiction Holding AB (“Realfiction” or the “Company”). The exercise period for the warrants

Johan Rask is appointed CEO of Insplorion

The Board of Insplorion announces today that it has appointed Johan Rask as the new CEO of Insplorion with effect from 1 February 2022. Johan Rask has extensive experience from previous employments and assignments, and the Board considers that he is the right person to drive the company's commercialization work into a new phase.In connection with the current CEO Patrik Dahlqvist being offered interesting opportunities in another industry, the board has after the summer conducted a dialogue with Patrik about the company's needs and focus in the future. Together, it has been concluded that

New data on lecanemab presented at the CTAD Alzheimer conference

Stockholm, November 15, 2021 - BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) and partner Eisai held several oral presentations at the 14[th] Clinical Trials on Alzheimer’s Disease (CTAD) conference, November 9-12, 2021, revealing new data on lecanemab (BAN2401), an investigational anti-amyloid beta protofibril antibody. The presentations provided further support for the encouraging data regarding lecanemab’s potential as a treatment for early Alzheimer’s disease previously seen in the Phase 2b as well as open label extension study. In addition, data presented showed the potential to use

Nightingale launches Nightingale Home and Nightingale Pro service models

Press release15 November 2021 at 9:00 (EET) Nightingale Health Plc (”Nightingale”) launches two new service models: Nightingale Home service model, in which the blood sample is taken by the consumer, and Nightingale Pro service model, in which the blood sample is taken by a healthcare professional at a laboratory. Nightingale Home service model includes the unique health index developed by Nightingale and the health indicators describing different health areas. In the Nightingale Home service model, the sample is taken as a fingerprick blood test with an easy-to-use device.

Hansa Biopharma to initiate Phase 3 study of imlifidase to treat anti-Glomerular Basement Membrane (anti-GBM) disease after successful pre-IND meeting with U.S. FDA

· Pivotal Phase 3 study to commence in 2022 and is expected to enroll approximately 50 patients across the U.S. and Europe · Advice procedure also initiated with the European Medicines Agency · Marks important milestone in the expansion of imlifidase into autoimmune diseases Lund, Sweden November 15, 2021. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announces its decision to initiate a pivotal Phase 3 clinical study of imlifidase to treat anti-GBM disease, following a successful pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (

SBB sells building rights to a JV together with Aspelin Ramm for SEK 450 million

Samhällsbyggnadsbolaget i Norden AB (publ) (“SBB”) has entered into a binding agreement to sell the property Göteborg Gamlestaden 2:8 for SEK 450m to a newly formed joint venture together with Aspelin Ramm. The property comprises approximately 21,000 sqm as well as additional building rights. “We believe a lot in Gamlestaden in Gothenburg, where we are a major player and where we have recently built a new building for SOS Alarm on the neighboring property. Through this collaboration with the locally strong developer Aspelin Ramm, we are convinced that we will develop the property into

KlaraBo intends to list on Nasdaq Stockholm and carry out a share issue

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEELAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, OR ANY OTHER JURISDICTION IN WHICH THE PUBLICATION, DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO ACQUIRE SECURITIES. PLEASE SEE ”IMPORTANT INFORMATION” AT THE END OF THE PRESS RELEASE. KlaraBo Sverige AB (publ) (”KlaraBo” or the ”Company”), a manager and developer of rental apartments

SSAB and Autoliv to collaborate on fossil-free steel in automotive safety products

Steel company SSAB and automotive safety supplier Autoliv have initiated a collaboration to research and develop fossil-free steel components for automotive safety products, such as airbags and seatbelts. Mikael Bratt, CEO of Autoliv (left) and Martin Lindqvist, CEO of SSAB (right). “We are looking forward to working with Autoliv and to start the process of research and development of innovative fossil-free steel components for their automotive safety products. We are initiating a number of pilot projects together with Autoliv with the aim to reduce climate impact and

Stora Enso shares converted

STORA ENSO OYJ STOCK EXCHANGE RELEASE 15 November 2021 at 9.00 EETDuring the 1 October 2021 – 31 October 2021 conversion period there were seven conversions and a total of 3,664 A shares were converted into R shares. The shares were recorded in the Finnish trade register today, 15 November 2021, and trading in the new R shares will start on 16 November 2021.Breakdown of shares after conversion: A shares 176 244 459R shares 612 375 528Total 788 619 987 Each A share and each ten R shares carry one vote. The total amount of votes after the conversion is at least 237 482 011.

UPM included in the Dow Jones Sustainability Index for 10 years in a row

(UPM, Helsinki, 15 November 2021 at 9:00 EET) – UPM has been listed in the Dow Jones European and World Sustainability Indices (DJSI) for 2021-2022 as the only company in its industry. The DJSI indices cover environmental, social and governance aspects of responsibility. “We are delighted and proud that our consistent commitment to sustainability has been recognised in this index for a decade,” says Sami Lundgren, Vice President, UPM Responsibility. “We congratulate UPM for being included in the Dow Jones European and World Sustainability Indices. DJSI distinction is a reflection of

There are no items matching the current filter
There are no more items matching the current filter
Back to top